Akso Health Group (NASDAQ: HX) Stock Competitors & Peer Comparison
See HX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
| MCK | $863.20 | +1.11% | 98.2B | 20.55 | $40.82 | +0.39% |
| COR | $319.18 | +0.66% | 61.2B | 18.35 | $17.15 | +0.76% |
| CAH | $228.91 | -2.53% | 53.5B | 21.90 | $10.43 | +0.89% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $88.47 | -0.92% | 10.1B | 16.66 | $5.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| PBH | $50.93 | -1.45% | 2.4B | 11.43 | $4.42 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| ACH | $1.24 | -6.44% | 99.9M | 1.92 | $0.68 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
HX vs MCK Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MCK has a market cap of 98.2B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while MCK trades at $863.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MCK's P/E ratio is 20.55. In terms of profitability, HX's ROE is -1.07%, compared to MCK's ROE of -1.94%. Regarding short-term risk, HX is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for HX.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
HX vs COR Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, COR has a market cap of 61.2B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while COR trades at $319.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas COR's P/E ratio is 18.35. In terms of profitability, HX's ROE is -1.07%, compared to COR's ROE of +1.06%. Regarding short-term risk, HX is more volatile compared to COR. This indicates higher risk in terms of short-term price fluctuations for HX.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
HX vs CAH Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CAH has a market cap of 53.5B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while CAH trades at $228.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CAH's P/E ratio is 21.90. In terms of profitability, HX's ROE is -1.07%, compared to CAH's ROE of -0.60%. Regarding short-term risk, HX is more volatile compared to CAH. This indicates higher risk in terms of short-term price fluctuations for HX.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
HX vs ABC Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ABC's P/E ratio is 21.92. In terms of profitability, HX's ROE is -1.07%, compared to ABC's ROE of +1.06%. Regarding short-term risk, HX is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for HX.Check ABC's competition here
Henry Schein, Inc. (NASDAQ: HSIC)
HX vs HSIC Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, HSIC has a market cap of 10.1B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while HSIC trades at $88.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas HSIC's P/E ratio is 16.66. In terms of profitability, HX's ROE is -1.07%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for HX.Check HSIC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
HX vs PDCO Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HX's ROE is -1.07%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HX is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for HX.Check PDCO's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
HX vs PBH Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while PBH trades at $50.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PBH's P/E ratio is 11.43. In terms of profitability, HX's ROE is -1.07%, compared to PBH's ROE of +0.09%. Regarding short-term risk, HX is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for HX.Check PBH's competition here
Owens & Minor, Inc. (NYSE: OMI)
HX vs OMI Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas OMI's P/E ratio is -0.47. In terms of profitability, HX's ROE is -1.07%, compared to OMI's ROE of +0.63%. Regarding short-term risk, HX is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for HX.Check OMI's competition here
Accendra Health, Inc. (NYSE: ACH)
HX vs ACH Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ACH has a market cap of 99.9M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while ACH trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ACH's P/E ratio is 1.92. In terms of profitability, HX's ROE is -1.07%, compared to ACH's ROE of +0.63%. Regarding short-term risk, HX is more volatile compared to ACH. This indicates higher risk in terms of short-term price fluctuations for HX.Check ACH's competition here
111, Inc. (NASDAQ: YI)
HX vs YI Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, YI has a market cap of 29.8M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while YI trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas YI's P/E ratio is -2.44. In terms of profitability, HX's ROE is -1.07%, compared to YI's ROE of +0.14%. Regarding short-term risk, HX is more volatile compared to YI. This indicates higher risk in terms of short-term price fluctuations for HX.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
HX vs WGRX Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas WGRX's P/E ratio is -0.33. In terms of profitability, HX's ROE is -1.07%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, HX is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for HX.Check WGRX's competition here
ZeroStack Corp. (NASDAQ: ZSTK)
HX vs ZSTK Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZSTK has a market cap of 6.2M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while ZSTK trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZSTK's P/E ratio is -0.12. In terms of profitability, HX's ROE is -1.07%, compared to ZSTK's ROE of -3.82%. Regarding short-term risk, HX is less volatile compared to ZSTK. This indicates lower risk in terms of short-term price fluctuations for HX.Check ZSTK's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
HX vs MEDS Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MEDS has a market cap of 3.8M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while MEDS trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MEDS's P/E ratio is N/A. In terms of profitability, HX's ROE is -1.07%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, HX is more volatile compared to MEDS. This indicates higher risk in terms of short-term price fluctuations for HX.Check MEDS's competition here
Zynex, Inc. (NASDAQ: ZYXI)
HX vs ZYXI Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HX's ROE is -1.07%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, HX is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for HX.Check ZYXI's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
HX vs SNYR Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, SNYR has a market cap of 1.2M. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while SNYR trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas SNYR's P/E ratio is -0.08. In terms of profitability, HX's ROE is -1.07%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HX is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for HX.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
HX vs RDGT Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, RDGT has a market cap of 724.3K. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while RDGT trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas RDGT's P/E ratio is -0.01. In terms of profitability, HX's ROE is -1.07%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, HX is more volatile compared to RDGT. This indicates higher risk in terms of short-term price fluctuations for HX.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
HX vs CVET Comparison August 2026
Akso Health Group (NASDAQ: HX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HX is priced at $2.24 on the NASDAQ, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CVET's P/E ratio is -69.97. In terms of profitability, HX's ROE is -1.07%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HX is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for HX.Check CVET's competition here